Use of omalizumab for management of idiopathic anaphylaxis
Lauren W. Kaminsky(Penn State Milton S. Hershey Medical Center), Taha Al‐Shaikhly(Pennsylvania State University), Kestutis Aukstuolis(University of Washington), Daniel Petroni(Allergy Asthma Research Institute)
Cited by 27
Related Papers
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
|JAMA|2019|271
Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
|JCI Insight|2019|188
A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
|EClinicalMedicine|2019|132
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
|New England Journal of Medicine|2023|129
Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy
|Annals of Allergy Asthma & Immunology|2018|103